{
    "pmcid": "8528929",
    "qa_pairs": {
        "How does the neutralizing activity of the monoclonal antibodies compare to the nanobody VHH-72 in the study?": [
            "Monoclonal antibodies demonstrated more potent neutralizing activity with sub-nanomolar IC50 values",
            "Monoclonal antibodies showed less potent neutralizing activity with higher IC50 values",
            "The nanobody VHH-72 demonstrated more potent neutralizing activity with sub-nanomolar IC50 values",
            "Both monoclonal antibodies and the nanobody VHH-72 showed similar neutralizing activity"
        ],
        "What advantage do nanobodies have over conventional antibodies according to the study?": [
            "Ability to bind to unique epitopes that might be inaccessible to larger antibodies",
            "Higher molecular weight allowing for better stability",
            "Increased production cost due to complex structure",
            "Reduced solubility compared to conventional antibodies"
        ],
        "What is the primary method used in the study for isolating high-affinity antibodies against SARS-CoV-2?": [
            "Single B cell screening",
            "Phage display",
            "Hybridoma technology",
            "CRISPR-Cas9 screening"
        ],
        "What potential future direction does the study suggest for the development of nanobodies?": [
            "Identifying nanobodies with broad neutralizing activity against multiple coronaviruses",
            "Focusing solely on monoclonal antibodies for therapeutic applications",
            "Developing nanobodies with reduced cross-reactivity to minimize side effects",
            "Creating nanobodies that only target a single SARS-CoV-2 variant"
        ],
        "Which monoclonal antibody mentioned in the study retained binding to the UK variant (B.1.1.7) but showed reduced binding to the South African variant (B.1.351)?": [
            "13I1",
            "12H2",
            "VHH-72",
            "11C3"
        ]
    }
}